Leukemia research reports · 2023

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.

СтатьяНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Nakaya Aya, Shibayama Hirohiko, Uoshima Nobuhiko, Yamamura Ryosuke, Yoshioka Satoshi, Imada Kazunori, Shimura Yuji, Hotta Masaaki, Matsui Toshimitsu, Kosugi Satoru, Hanamoto Hitoshi, Uchiyama Hitoji, Yoshihara Satoshi, Fuchida Shin-Ichi, Onda Yoshiyuki, Tanaka Yasuhiro, Ohta Kensuke, Matsuda Mitsuhiro, Kanda Junya, Yoko Adachi, Kiyota Miki, Kawata Eri, Takahashi Ryoichi, Fukushima Kentaro, Tanaka Hirokazu, Yagi Hideo, Takakuwa Teruhito, Hosen Naoki, Ito Tomoki, Shimazaki Chihiro, Takaori-Kondo Akifumi, Kuroda Junya, Matsumura Itaru, Hino Masayuki

Аннотация

To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (n = 338, 72 %) was 6.5 years, patients with del(17p) (n = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (n = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (n = 18, 4 %) was 2.1 years (p = 0.032). Patients with double-positive CAs had a significantly worse prognosis.

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.

Ошибки и ограничения

Аннотация